1. Home
  2. LASR vs RCUS Comparison

LASR vs RCUS Comparison

Compare LASR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$70.02

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$28.42

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
RCUS
Founded
2000
2015
Country
United States
United States
Employees
N/A
601
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.6B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
LASR
RCUS
Price
$70.02
$28.42
Analyst Decision
Strong Buy
Buy
Analyst Count
9
10
Target Price
$54.31
$31.90
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
62.99
N/A
EPS
0.01
N/A
Revenue
$191,359,000.00
$247,000,000.00
Revenue This Year
$10.91
N/A
Revenue Next Year
$14.32
$45.62
P/E Ratio
$7,300.00
N/A
Revenue Growth
38.09
N/A
52 Week Low
$18.62
$8.84
52 Week High
$86.95
$31.74

Technical Indicators

Market Signals
Indicator
LASR
RCUS
Relative Strength Index (RSI) 50.50 51.38
Support Level $64.13 $20.20
Resistance Level $72.47 $28.72
Average True Range (ATR) 6.14 1.33
MACD 0.63 -0.16
Stochastic Oscillator 63.00 50.83

Price Performance

Historical Comparison
LASR
RCUS

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: